Context Therapeutics is trading 24.2% down at $0.53 in after-hours trading as investors position ahead of the company’s upcoming quarterly financial results.
- The company is scheduled to release its Q2 2026 earnings report before the market open on August 6, 2026.
- The sharp decline follows a regular-session close of $0.69, with thin after-hours liquidity likely amplifying the downward move.